SUPERNUS PHARMACEUTICALS ($SUPN) posted quarterly earnings results for Q1 2026 on Tuesday, May 5th. The company reported earnings of $0.59 per share, beating estimates of $0.30 by $0.29. The company also reported revenue of $207,710,000, beating estimates of $196,776,023 by $10,933,977.
Stock price change since market close: +4.7%
You can see Quiver Quantitative's $SUPN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SUPERNUS PHARMACEUTICALS Insider Trading Activity
SUPERNUS PHARMACEUTICALS insiders have traded $SUPN stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $SUPN stock by insiders over the last 6 months:
- PADMANABH P. BHATT (Sr. VP of IP, CSO) has made 0 purchases and 7 sales selling 107,960 shares for an estimated $5,419,983.
- JACK A. KHATTAR (President, CEO) has made 0 purchases and 3 sales selling 35,000 shares for an estimated $1,763,124.
- FRANK MOTTOLA (SVP, Chief Tech. Ops. Officer) has made 0 purchases and 3 sales selling 21,623 shares for an estimated $1,095,223.
- GEORGES GEMAYEL has made 0 purchases and 2 sales selling 18,787 shares for an estimated $1,002,811.
- WILLIAM TODD HORICH (SVP, Commercial Operations) has made 0 purchases and 2 sales selling 8,877 shares for an estimated $483,797.
- FREDERICK M. HUDSON sold 5,369 shares for an estimated $271,725
- BETHANY SENSENIG has made 0 purchases and 2 sales selling 4,475 shares for an estimated $228,264.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
SUPERNUS PHARMACEUTICALS Hedge Fund Activity
We have seen 163 institutional investors add shares of SUPERNUS PHARMACEUTICALS stock to their portfolio, and 159 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MACQUARIE GROUP LTD removed 2,531,537 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $125,817,388
- MILLENNIUM MANAGEMENT LLC added 2,293,773 shares (+662.4%) to their portfolio in Q4 2025, for an estimated $114,000,518
- WOODLINE PARTNERS LP removed 1,263,811 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $62,811,406
- CITADEL ADVISORS LLC removed 963,967 shares (-68.0%) from their portfolio in Q4 2025, for an estimated $47,909,159
- RUBRIC CAPITAL MANAGEMENT LP removed 595,366 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $29,589,690
- ASSENAGON ASSET MANAGEMENT S.A. added 530,618 shares (+inf%) to their portfolio in Q1 2026, for an estimated $27,427,644
- POINT72 ASSET MANAGEMENT, L.P. added 503,316 shares (+28.6%) to their portfolio in Q4 2025, for an estimated $25,014,805
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
SUPERNUS PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $SUPN stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SUPN stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/03, 12/11 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
